大成生化科技(00809.HK)預計中期業績出現重大改善
格隆匯7月8日丨大成生化科技(00809.HK)公佈,集團於截至2021年5月31日止五個月錄得淨利潤約5.935億港元。因此,預期集團截至2021年6月30日止六個月的中期業績將較2020年同期所錄得約9.028億港元的虧損淨額出現重大改善。
該重大改善主要是由於集團繼由集團與長春潤德所訂立的回購協議以及由長春大金倉玉米收儲有限公司與長春潤德所訂立的其他回購協議的完成(兩者均於2021年3月31日落實)後,確認超過10億港元的一次性收益所致。
進一步宣佈,此前披露有關集團若干附屬公司暫停營運的情況於該期間持續。因此,預期集團於該期間的收益較2020年同期將錄得不超過40.0%的減幅。儘管如此,根據初步審閲,倘不計及確認回購協議及其他回購協議產生的一次性收益,集團截至2021年5月31日止五個月的虧損淨額亦較2020年同期錄得約10.0%的減幅。集團將繼續致力落實其他主要未償還債務的債務重組計劃,以改善其財務狀況並在實際可行情況下儘快恢復上述附屬公司的營運。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.